Добавил:
Upload Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Prescriber's Guide_ Stahl's Ess - Stephen M. Stahl.docx
Скачиваний:
1
Добавлен:
01.07.2025
Размер:
3 Мб
Скачать
☆

Breast Feeding

• Unknown if vilazodone is secreted in human breast milk, but all psychotropics assumed to be secreted in breast milk

• Trace amounts may be present in nursing children whose mothers are on vilazodone

• If child becomes irritable or sedated, breast feeding or drug may need to be discontinued

• Immediate postpartum period is a high-risk time for depression, especially in women who have had prior depressive episodes, so drug may need to be reinstituted late in the third trimester or shortly after childbirth to prevent a recurrence during the postpartum period

• Must weigh benefits of breast feeding with risks and benefits of antidepressant treatment versus nontreatment to both the infant and the mother

• For many patients, this may mean continuing treatment during breast feeding

VILAZODONE: THE ART OF PSYCHOPHARMACOLOGY

Potential Advantages

• Patients with sexual dysfunction on an SSRI/SNRI or who wish to avoid sexual dysfunction on an antidepressant

• Patients with weight gain on another antidepressant or who wish to avoid weight gain on an antidepressant

• Patients with mixed anxiety and depression

Potential Disadvantages

• Patients who cannot take medication reliably with food

• Patients sensitive to gastrointestinal side effects such as diarrhea and nausea

Primary Target Symptoms

• Depressed mood

• Anxiety

Pearls

• Serotonin 1A partial agonist property is a unique mechanism of action among approved antidepressants

• First member of a new antidepressant class, SPARIs, or serotonin partial agonist reuptake inhibitors

• Relative lack of sexual dysfunction and weight gain compared to many other antidepressants that block serotonin reuptake may be due to the serotonin 1A partial agonist properties of vilazodone

• High doses would theoretically raise brain serotonin levels more robustly than the standard dose, and may improve efficacy in some patients but reduce tolerability in some patients

• Consider doses of 50–80 mg daily for patients with treatment-resistant depression or treatment-resistant OCD and other anxiety disorders

• Consider for patients with comorbid anxiety disorders plus depression

• Nonresponse to vilazodone in elderly may require consideration of mild cognitive impairment or Alzheimer disease

Suggested Reading

Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2012;66(4):356–68.

Dawson LA, Watson JM. Vilazodone: a 5HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Therapeutics 2009;15:107–17.

Laughren TP, Gobburu J, Temple RJ, et al. Vilazodone: clinical basis for the US Food and Drug Administration’s approval of a new antidepressant. J Clin Psychiatry 2011;72(9):1166–73.

Rickels K, Athanasiou M, Robinson D, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;e1–e8.

VORTIOXETINE

VORTIOXETINE: THERAPEUTICS

Brands

• Brintellix

see index for additional brand names

Generic?

No

Class

• Multimodal antidepressant

Commonly Prescribed for

(bold for FDA approved)

• Major depressive disorder

• Generalized anxiety disorder

• Cognitive symptoms associated with depression

• Geriatric depression

How the Drug Works

• Increases release of several different neurotransmitters (serotonin, norepinephrine, dopamine, glutamate, acetylcholine, and histamine) and reduces the release of GABA through 3 different modes of action

• Mode 1: blocks serotonin reuptake pump (serotonin transporter)

• Mode 2: binds to G protein–linked receptors (full agonist at serotonin 1A receptors, partial agonist at serotonin 1B receptors, antagonist at serotonin 1D and serotonin 7 receptors)

• Mode 3: binds to ion channel–linked receptors (antagonist at serotonin 3 receptors)

• Full agonist actions at presynaptic somatodendritic serotonin 1A autoreceptors may theoretically enhance serotonergic activity and contribute to antidepressant actions

• Full agonist actions at postsynaptic serotonin 1A receptors may theoretically diminish sexual dysfunction caused by serotonin reuptake inhibition

• Antagonist actions at serotonin 3 receptors may theoretically enhance noradrenergic, acetylcholinergic, and glutamatergic activity and contribute to antidepressant and pro-cognitive actions

• Antagonist actions at serotonin 3 receptors may theoretically reduce nausea and vomiting caused by serotonin reuptake inhibition

• Antagonist actions at serotonin 7 receptors may theoretically contribute to antidepressant and pro-cognitive actions as well as reduce insomnia caused by serotonin reuptake inhibition

• Partial agonist actions at serotonin 1B receptors may enhance not only serotonin release, but also acetylcholine and histamine release

• Antagonist actions at serotonin 1D receptors may enhance serotonin release and may also theoretically enhance the release of pro-cognitive neurotransmitters and thereby enhance pro-cognitive actions

Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]